This Evidence Based Case-Report is made in line with the SCARE criteria []. A 74-year-old female came with post-menopausal bleeding lasting for a month. The bleeding occurred intermittently, approximately 1–2 pads each day. The patient also complained of intermittent pelvic tenderness which was more severe on the right side. Patient had 2 living children via spontaneous vaginal delivery with no abortion history, she had menopause 22 years ago. Past personal and familial medical history were unremarkable. Normal findings were found upon physical and gynecological examinations. Initial ultrasonography (July 31st, 2018) findings suggested that the uterus cavity was filled with fluid due to blockage at the endocervix. However, the cause could not be determined. Patient was then referred to a tertiary hospital for further investigation. Upon hysteroscopic examination by a gynecology oncology consultant with more than 10 years of experience, several glomerular mass with atypical vessels resembling malignant endometrial lesion were found. The appearance from the biopsy was suggestive for serous Endometrial Carcinoma grade II presumably from the endometrium. There were neither normal endometrial tissue nor hyperplastic zone to be identified (). Histopathologic specimen showing cancerous cells with no normal tissue (A) 40x zoom and (B) 100x zoom. (C). Glomerular growing mass with atypical vessels. MRI examination (September 1st, 2018) found two masses: at the tube and endometrium. Endometrial mass was prominent to anterior junctional zone with 13 mm thickness, did not invade the myometrium, and covered <50% of the endometrial surface in accordance to T1A-N0-M0 staging []. There were right tubal mass sized 29/30/31 mm and right hydrosalpinx with T2A-N0-M0 staging []. There were no signs of metastasis. The right adnexa mass was attached to the right wall of the uterus with suspicion towards ovarian cyst with of 34/37/42 mm, which is not part of the discussion. Other findings were within normal limit (). Follow-up USG on September 25th, 2018 revealed collapsed uterine cavity. Presence of intra-cavitary malignancy could not be ruled out. There was no widening of parailiac and bilateral of paraaortic lymph nodes. On October 4th, 2018 surgery was performed by a senior gynecology oncology consultant with more than 15 years of experience. Adhesiolysis and surgical staging laparotomy (total abdominal hysterectomy, bilateral salphingo-oophorectomy, pelvic lymphadenectomy, and para-aorta lymphadenectomy) were conducted. Macroscopically, there was a normal-sized uterus with thin endometrium and no evidence of tumor in the uterine cavity. The fallopian tumor measured 30/25/20 mm, was brown-yellowish in color but white and fibrous on the inside. From final histopathology expertise, the patient had high-grade serous carcinoma from the right fallopian tube (). Para-aortic, right pelvic, and left pelvic lymph nodes showed histiocytosis sinus and no metastasis. The final diagnosis was then Fallopian Tube Cancer stage IIB. The patient was then planned to receive three cycles of chemotherapy using carboplatin and paclitaxel. The patient tolerated the chemotherapy well with mild complain of constipation that did not require any further medication to resolve. No recurrence was reported one year after the procedure was done. Regarding the whole experience, the patient understands that FTC is often misdiagnosed due to its rare occurrence and non-distinctive symptoms. The patient is also satisfied that the clinicians have put appropriate efforts to diagnose the origin of the tumor.